Cluster features in fibrosing interstitial lung disease and associations with prognosis

被引:0
作者
Wang, Yuanying [1 ]
Sun, Di [1 ]
Wang, Jingwei [1 ]
Yu, Shiwen [1 ,2 ]
Wu, Na [1 ,2 ]
Ye, Qiao [1 ,2 ]
机构
[1] Capital Med Univ, Affiliated Beijing Chao Yang Hosp, Beijing Inst Resp Med, Clin Ctr Interstitial Lung Dis, Beijing, Peoples R China
[2] Capital Med Univ, Affiliated Beijing Chao Yang Hosp, Dept Occupat Med & Toxicol, Beijing, Peoples R China
关键词
Pulmonary fibrosis; Interstitial lung diseases; Cluster analysis; Prognosis; Acute exacerbation; IDIOPATHIC PULMONARY-FIBROSIS; ACUTE EXACERBATION; DOUBLE-BLIND; IDENTIFICATION; PIRFENIDONE; DIAGNOSIS; UPDATE;
D O I
10.1186/s12890-023-02735-7
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Clustering is helpful in identifying subtypes in complex fibrosing interstitial lung disease (F-ILD) and associating them with prognosis at an early stage of the disease to improve treatment management. We aimed to identify associations between clinical characteristics and outcomes in patients with F-ILD.Methods Retrospectively, 575 out of 926 patients with F-ILD were eligible for analysis. Four clusters were identified based on baseline data using cluster analysis. The clinical characteristics and outcomes were compared among the groups.Results Cluster 1 was characterized by a high prevalence of comorbidities and hypoxemia at rest, with the worst lung function at baseline; Cluster 2 by young female patients with less or no smoking history; Cluster 3 by male patients with highest smoking history, the most noticeable signs of velcro crackles and clubbing of fingers, and the severe lung involvement on chest image; Cluster 4 by male patients with a high percentage of occupational or environmental exposure. Clusters 1 (median overall survival [OS] = 7.0 years) and 3 (OS = 5.9 years) had shorter OS than Clusters 2 (OS = not reached, Cluster 1: p < 0.001, Cluster 3: p < 0.001) and 4 (OS = not reached, Cluster 1: p = 0.004, Cluster 3: p < 0.001). Clusters 1 and 3 had a higher cumulative incidence of acute exacerbation than Clusters 2 (Cluster 1: p < 0.001, Cluster 3: p = 0.014) and 4 (Cluster 1: p < 0.001, Cluster 3: p = 0.006). Stratification by using clusters also independently predicted acute exacerbation (p < 0.001) and overall survival (p < 0.001).Conclusions The high degree of disease heterogeneity of F-ILD can be underscored by four clusters based on clinical characteristics, which may be helpful in predicting the risk of fibrosis progression, acute exacerbation and overall survival.
引用
收藏
页数:11
相关论文
共 34 条
[1]   Phenotypic Clusters Predict Outcomes in a Longitudinal Interstitial Lung Disease Cohort [J].
Adegunsoye, Ayodeji ;
Oldham, Justin M. ;
Chung, Jonathan H. ;
Montner, Steven M. ;
Lee, Cathryn ;
Witt, Leah J. ;
Stahlbaum, Danielle ;
Bermea, Rene S. ;
Chen, Lena W. ;
Hsu, Scully ;
Husain, Aliya N. ;
Noth, Imre ;
Vij, Rekha ;
Strek, Mary E. ;
Churpek, Matthew .
CHEST, 2018, 153 (02) :349-360
[2]   Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond [J].
Aimo, Alberto ;
Spitaleri, Giosafat ;
Nieri, Dario ;
Tavanti, Laura Maria ;
Meschi, Claudia ;
Panichella, Giorgia ;
Lupon, Josep ;
Pistelli, Francesco ;
Carrozzi, Laura ;
Bayes-Genis, Antoni ;
Emdin, Michele .
CARDIAC FAILURE REVIEW, 2022, 8
[3]  
American Thoracic Society European Respiratory Society, 2002, Am J Respir Crit Care Med, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]
[4]   Clinical implications of idiopathic pulmonary arterial hypertension phenotypes defined by cluster analysis [J].
Badagliacca, Roberto ;
Rischard, Franz ;
Papa, Silvia ;
Kubba, Saad ;
Vanderpool, Rebecca ;
Yuan, Jason X-J ;
Garcia, Joe G. N. ;
Airhart, Sophia ;
Poscia, Roberto ;
Pezzuto, Beatrice ;
Manzi, Giovanna ;
Miotti, Cristiano ;
Luongo, Federico ;
Scoccia, Gianmarco ;
Sciomer, Susanna ;
Torre, Roberto ;
Fedele, Francesco ;
Vizza, Carmine Dario .
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04) :310-320
[5]   Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial [J].
Behr, Juergen ;
Prasse, Antje ;
Kreuter, Michael ;
Johow, Johannes ;
Rabe, Klaus F. ;
Bonella, Francesco ;
Bonnet, Reiner ;
Grohe, Christian ;
Held, Matthias ;
Wilkens, Heinrike ;
Hammerl, Peter ;
Koschel, Dirk ;
Blaas, Stefan ;
Wirtz, Hubert ;
Ficker, Joachim H. ;
Neumeister, Wolfgang ;
Schoenfeld, Nicolas ;
Claussen, Martin ;
Kneidinger, Nikolaus ;
Frankenberger, Marion ;
Hummler, Simone ;
Kahn, Nicolas ;
Tello, Silke ;
Freise, Julia ;
Welte, Tobias ;
Neuser, Petra ;
Guenther, Andreas .
LANCET RESPIRATORY MEDICINE, 2021, 9 (05) :476-486
[6]   Acute Exacerbation of Idiopathic Pulmonary Fibrosis An International Working Group Report [J].
Collard, Harold R. ;
Ryerson, Christopher J. ;
Corte, Tamera J. ;
Jenkins, Gisli ;
Kondoh, Yasuhiro ;
Lederer, David J. ;
Lee, Joyce S. ;
Maher, Toby M. ;
Wells, Athol U. ;
Antoniou, Katerina M. ;
Behr, Juergen ;
Brown, Kevin K. ;
Cottin, Vincent ;
Flaherty, Kevin R. ;
Fukuoka, Junya ;
Hansell, David M. ;
Johkoh, Takeshi ;
Kaminski, Naftali ;
Kim, Dong Soon ;
Kolb, Martin ;
Lynch, David A. ;
Myers, Jeffrey L. ;
Raghu, Ganesh ;
Richeldi, Luca ;
Taniguchi, Hiroyuki ;
Martinez, Fernando J. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 194 (03) :265-275
[7]   Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis [J].
Collins, Bridget F. ;
Raghu, Ganesh .
EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
[8]   Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases [J].
Cottin, Vincent ;
Hirani, Nikhil A. ;
Hotchkin, David L. ;
Nambiar, Anoop M. ;
Ogura, Takashi ;
Otaola, Maria ;
Skowasch, Dirk ;
Park, Jong Sun ;
Poonyagariyagorn, Hataya K. ;
Wuyts, Wim ;
Wells, Athol U. .
EUROPEAN RESPIRATORY REVIEW, 2018, 27 (150)
[9]   Statistical power for cluster analysis [J].
Dalmaijer, Edwin S. ;
Nord, Camilla L. ;
Astle, Duncan E. .
BMC BIOINFORMATICS, 2022, 23 (01)
[10]   Nintedanib in Progressive Fibrosing Interstitial Lung Diseases [J].
Flaherty, K. R. ;
Wells, A. U. ;
Cottin, V ;
Devaraj, A. ;
Walsh, S. L. F. ;
Inoue, Y. ;
Richeldi, L. ;
Kolb, M. ;
Tetzlaff, K. ;
Stowasser, S. ;
Coeck, C. ;
Clerisme-Beaty, E. ;
Rosenstock, B. ;
Quaresma, M. ;
Haeufel, T. ;
Goeldner, R-G ;
Schlenker-Herceg, R. ;
Brown, K. K. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18) :1718-1727